1-9 of 9
Yayoi Fujioka
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Abstract A126: Acquired resistance to trastuzumab/pertuzumab, or to T-DM1 in vivo can be overcome by HER2 inhibition with TAS0728

Hiroki Irie, Rumi Kawabata, Yayoi Fujioka, Fumio Nakagawa, Hideki Nagase, Hiraku Itadani, Kimihiro Ito, Junji Uchida, Shuichi Ohkubo, Kenichi Matsuo, Takeshi Sagara, Teruhiro Utsugi
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2019) 18 (12_Supplement): A126.
https://doi.org/10.1158/1535-7163.TARG-19-A126
Published: 01 December 2019
View article titled, Abstract A126: Acquired resistance to trastuzumab/pertuzumab, or to T-DM1 <em>in vivo</em> can be overcome by HER2 inhibition with TAS0728
Journal Articles

TAS0728, A Covalent-binding, HER2-selective Kinase Inhibitor Shows Potent Antitumor Activity in Preclinical Models

Hiroki Irie, Kimihiro Ito, Yayoi Fujioka, Kei Oguchi, Akio Fujioka, Akihiro Hashimoto, Hirokazu Ohsawa, Kenji Tanaka, Kaoru Funabashi, Hikari Araki, Yuichi Kawai, Tadashi Shimamura, Renu Wadhwa, Shuichi Ohkubo, Kenichi Matsuo
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2019) 18 (4): 733–742.
https://doi.org/10.1158/1535-7163.MCT-18-1085
Published: 01 April 2019
View article titled, TAS0728, A Covalent-binding, HER2-selective Kinase Inhibitor Shows Potent Antitumor Activity in Preclinical Models
Open the PDF for TAS0728, A Covalent-binding, HER2-selective Kinase Inhibitor Shows Potent Antitumor Activity in Preclinical Models in another window
Includes: Supplementary data
Journal Articles

Abstract B179: TAS0728, a HER2-selective covalent inhibitor, demonstrates potent antitumor effect as a single agent and in combination with anti-HER2 antibodies in HER2-overexpressed tumor models

Hiroki Irie, Kei Oguchi, Kimihiro Ito, Yayoi Fujioka, Yuichi Kawai, Tadashi Shimamura, Hikari Araki, Akio Fujioka, Fumio Nakagawa, Rumi Kawabata, Hideki Nagase, Takeshi Sagara, Junji Uchida, Kenichi Matsuo, Teruhiro Utsugi, Yoshikazu Iwasawa
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2018) 17 (1_Supplement): B179.
https://doi.org/10.1158/1535-7163.TARG-17-B179
Published: 01 January 2018
View article titled, Abstract B179: TAS0728, a HER2-selective covalent inhibitor, demonstrates potent antitumor effect as a single agent and in combination with anti-HER2 antibodies in HER2-overexpressed tumor models
Journal Articles

Abstract A108: TAS-115, a VEGFR/MET-targeted kinase inhibitor, potently suppresses HGF-induced aggressive bone and systemic metastasis in HGF knock-in mice bearing UM-UC-3 bladder tumors

Yukari Yamada, Hidenori Fujita, Yayoi Fujioka, Naomoto Harada, Akihiro Hashimoto, Tomonori Haruma, Shingo Tsuzi, Ryouto Fujita, Kenichi Matsuo, Teruhiro Utsugi, Kazuhiko Yonekura
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2015) 14 (12_Supplement_2): A108.
https://doi.org/10.1158/1535-7163.TARG-15-A108
Published: 01 December 2015
View article titled, Abstract A108: TAS-115, a VEGFR/MET-targeted kinase inhibitor, potently suppresses HGF-induced aggressive bone and systemic metastasis in HGF knock-in mice bearing UM-UC-3 bladder tumors
Journal Articles

The Novel VEGF Receptor/MET–Targeted Kinase Inhibitor TAS-115 Has Marked In Vivo Antitumor Properties and a Favorable Tolerability Profile

Hidenori Fujita, Kazutaka Miyadera, Masanori Kato, Yayoi Fujioka, Hiroaki Ochiiwa, Jinhong Huang, Kimihiro Ito, Yoshimi Aoyagi, Toru Takenaka, Takamasa Suzuki, Satoko Ito, Akihiro Hashimoto, Takashi Suefuji, Kosuke Egami, Hideki Kazuno, Yoshimitsu Suda, Kazuto Nishio, Kazuhiko Yonekura
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2013) 12 (12): 2685–2696.
https://doi.org/10.1158/1535-7163.MCT-13-0459
Published: 05 December 2013
View article titled, The Novel VEGF Receptor/MET–Targeted Kinase Inhibitor TAS-115 Has Marked <em>In Vivo</em> Antitumor Properties and a Favorable Tolerability Profile
Open the PDF for The Novel VEGF Receptor/MET–Targeted Kinase Inhibitor TAS-115 Has Marked <em>In Vivo</em> Antitumor Properties and a Favorable Tolerability Profile in another window
Includes: Supplementary data
Journal Articles

Abstract A272: Intermittent treatment with TAS-120, an irreversible FGFR inhibitor, is effective in tumors harboring a FGFR gene abnormality.

Yoko Nakatsuru, Hiroaki Ochiiwa, Hiroshi Sootome, Hidenori Fujita, Akihiro Hashimoto, Yoshihiro Shibata, Masato Chiba, Yayoi Fujioka, Kazuhiro Yonekura, Hiroshi Hirai, Teruhiro Utsugi
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2013) 12 (11_Supplement): A272.
https://doi.org/10.1158/1535-7163.TARG-13-A272
Published: 01 November 2013
View article titled, Abstract A272: Intermittent treatment with TAS-120, an irreversible FGFR inhibitor, is effective in tumors harboring a FGFR gene abnormality.
Journal Articles

Abstract A271: TAS-120, an irreversible FGFR inhibitor, was effective in tumors harboring FGFR mutations, refractory or resistant to ATP competitive inhibitors .

Hiroshi Sootome, Yayoi Fujioka, Akihiro Miura, Hidenori Fujita, Hiroshi Hirai, Teruhiro Utsugi
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2013) 12 (11_Supplement): A271.
https://doi.org/10.1158/1535-7163.TARG-13-A271
Published: 01 November 2013
View article titled, Abstract A271: TAS-120, an irreversible FGFR inhibitor, was effective in tumors harboring FGFR mutations, refractory or resistant to ATP competitive inhibitors .
Journal Articles

Abstract A270: TAS-120, a highly potent and selective irreversible FGFR inhibitor, is effective in tumors harboring various FGFR gene abnormalities.

Hiroaki Ochiiwa, Hidenori Fujita, Kimihiro Itoh, Hiroshi Sootome, Akihiro Hashimoto, Yayoi Fujioka, Yoko Nakatsuru, Nobuyuki Oda, Kazuhiko Yonekura, Hiroshi Hirai, Teruhiro Utsugi
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2013) 12 (11_Supplement): A270.
https://doi.org/10.1158/1535-7163.TARG-13-A270
Published: 01 November 2013
View article titled, Abstract A270: TAS-120, a highly potent and selective irreversible FGFR inhibitor, is effective in tumors harboring various FGFR gene abnormalities.
Journal Articles

Abstract A245: TAS-115, a novel potent dual MET/VEGFRs inhibitor, has highly safer profile leading to more potent efficacy in vivo.

Masanori Kato, Hidenori Fujita, Kazutaka Miyadera, Yayoi Fujioka, Hiroaki Ochiiwa, Jinhong Huang, Kimihiro Ito, Yoshimi Aoyagi, Toru Takenaka, Takamasa Suzuki, Satoko Ito, Akihiro Hashimoto, Takashi Suefuji, Ayako Sato, Kosuke Egami, Hideki Kazuno, Yoshimitsu Suda, Kazuhiko Yonekura
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2011) 10 (11_Supplement): A245.
https://doi.org/10.1158/1535-7163.TARG-11-A245
Published: 12 November 2011
View article titled, Abstract A245: TAS-115, a novel potent dual MET/VEGFRs inhibitor, has highly safer profile leading to more potent efficacy in vivo.